findmyKOL
Clinical trialNCT06031272CompletedPhase 1Interventional

Pausing Antiretroviral Treatment Under Structured Evaluation

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment32HIV-1-infection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to see if it is safe to give the study antibodies (3BNC117-LS-J and 10-1074-LS-J) by intravenous infusion to people with HIV (PWH), and to see if they cause any side effects. In addition, to see how the study antibodies affect the level of HIV in the blood when participants are not taking regular HIV treatment for an extended period. This extended period of not taking regular HIV treatment is called an analytical treatment interruption (ATI).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Botswana
  • Gaborone Crs (12701)

    Molepolole, Botswana

Malawi
  • Blantyre Crs (30301)

    Blantyre, Malawi

  • Lilongwe Malawi Crs (12001)

    Lilongwe, Malawi

South Africa
  • Ward 21 Crs (31966)

    Johannesburg, Gauteng, South Africa

  • Soweto Hvtn Crs (30351)

    Soweto, Gauteng, South Africa

  • Caprisa Ethekwini Crs (31422)

    Durban, KwaZulu-Natal, South Africa

  • Aurum Institute Klerksdorp Crs (30325)

    Klerksdorp, North West, South Africa

  • Rustenburg Crs (31684)

    Rustenburg, North West, South Africa

  • Groote Schuur Hiv Crs (31708)

    Cape Town, Western Cape, South Africa

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

10-1074-LS-J3BNC117-LS-JPlacebo for 10-1074-LS-JPlacebo for 3BNC117-LS-J
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 May 2024
Primary completion
14 Oct 2025
Completion
25 Jun 2026
Last update posted
17 Aug 2026
Registered enrollment
32
Registry id
NCT06031272
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.